Furthermore, the IGF-1R signaling pathway is associated with resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) used for the treatment of NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.